BioWorld

July 27, 2007

Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs

Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today) Read More

Exelixis Moving Forward On XL647 After GSK Declines

ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes

Aspreva Restructures, Plans To Look Beyond CellCept

Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...